HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pegaptanib sodium for ocular vascular disease.

Abstract
Pegaptanib sodium (Macugen) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF) 165 , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF 121 . After more than 10 years in development and preclinical study, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Its excellent ocular and systemic safety profile has also been confirmed in patients receiving up to three years of therapy. Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. Notably, pegaptanib was the first available aptamer approved for therapeutic use in humans and the first VEGF inhibitor available for the treatment of ocular vascular diseases.
AuthorsDhananjay Shukla, Perumalsamy Namperumalsamy, Mauro Goldbaum, Emmett T Cunningham Jr
JournalIndian journal of ophthalmology (Indian J Ophthalmol) 2007 Nov-Dec Vol. 55 Issue 6 Pg. 427-30 ISSN: 0301-4738 [Print] India
PMID17951898 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Aptamers, Nucleotide
  • Vascular Endothelial Growth Factor A
  • pegaptanib
Topics
  • Animals
  • Aptamers, Nucleotide (therapeutic use)
  • Humans
  • Retinal Diseases (drug therapy, metabolism)
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: